{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-027986","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.348183+00:00","generated_at":"2026-06-01T07:24:29.632135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roivant reports FY2024 GAAP income from continuing ops $4.2B on $5.3B Telavant gain; Q4 loss $182.5M","bullets":["Net product revenue from VTAMA (psoriasis) $75.1M for FY2024; over 385K prescriptions since launch.","Cash, cash equivalents and restricted cash $6.6B at March 31, 2024; after $648.4M share repurchase from Sumitomo, pro forma $5.9B.","Non-GAAP loss from continuing operations $799.9M for FY2024 vs $924.3M prior year.","Dermavant debt renegotiated reducing potential payments by over $300M; $225M reduction expected over next three fiscal years.","Pipeline: Priovant to initiate pivotal brepocitinib trial in NIU in H2 2024; Immunovant expects 4-5 registrational studies by March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-027986","json":"https://secwatch.observer/filing/0001140361-24-027986.json","markdown":"https://secwatch.observer/filing/0001140361-24-027986.md","text":"https://secwatch.observer/filing/0001140361-24-027986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124027986/0001140361-24-027986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124027986/ef20030255_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:24:29.632135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}